{
  "abstract": "IntroductionAcute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with variable responses to standard 7 + 3 induction therapy. Although transcriptional profiling can capture biological phenotypes beyond genetic mutations, regimen-specific predictive biomarkers for 7 + 3 therapy have not been established due to methodological limitations in existing studies.MethodsTo identify transcriptomic signatures for 7 + 3 response, we analyzed two ethnically diverse AML cohorts: OHSU BeatAML2.0 (n = 264) and SIH/JIH/ZIH AML (n = 582). Machine learning algorithms, including least absolute shrinkage and selection operator (LASSO), and cross-cohort intersection analysis were employed to identify candidate genes associated with 7 + 3 therapy outcomes. The identified candidates were further evaluated using qRT-PCR in an independent AML patient cohort (n = 58) and cytarabine sensitivity assays in AML cell lines.ResultsIntersection analysis identified seven candidate genes showing concordant associations with refractory response in OHSU and poor overall survival in SIH/JIH/ZIH. In the independent clinical cohort, only 2 of the 7 candidates, TMEM150C and F2R, were reliably detectable, with significantly elevated expression in refractory patients (4.2-fold and 2.9-fold, respectively). AML cell lines with higher TMEM150C and F2R expression also exhibited reduced cytarabine sensitivity.DiscussionThese findings from ethnically diverse cohorts, independent patient validation, and functional studies suggest that TMEM150C and F2R may serve as potential predictive biomarkers for 7 + 3 therapy response in AML, enabling personalized treatment selection.",
  "abstract_shown": true,
  "affiliations": [
    "Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea",
    "Department of Biochemistry, College of Medicine, Inje University, Busan, Republic of Korea",
    "Department of Biochemistry, College of Medicine, Dongguk University, Gyeongju, Republic of Korea",
    "Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yu-Jeong Choi"
    },
    {
      "affs": [
        0
      ],
      "name": "Jiwoo Kim"
    },
    {
      "affs": [
        0
      ],
      "name": "Xuan Linh Mai"
    },
    {
      "affs": [
        0
      ],
      "name": "Arvie Camille V. de Guzman"
    },
    {
      "affs": [
        1
      ],
      "name": "Yong Jin An"
    },
    {
      "affs": [
        0
      ],
      "name": "Han Sun Kim"
    },
    {
      "affs": [
        2
      ],
      "name": "Han Sun Kim"
    },
    {
      "affs": [
        3
      ],
      "name": "Byung-Sik Cho"
    },
    {
      "affs": [
        0
      ],
      "name": "Sunghyouk Park"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ey116g649ayhp.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1926332",
  "fulltext_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1926332/full",
  "id": "ey116g649ayhp",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://doi.org/10.3389/fonc.2026.1926332",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2720|Acute Myeloid Leukemia Research"
    ]
  ],
  "openalex": "W7223358861",
  "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1926332/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-23",
  "publisher": "Frontiers Media S.A.",
  "ris": "https://research.draconitic.com/paper/ey116g649ayhp.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:19Z",
      "native_id": "052950310cc84f83b3c47e79914e3ba7",
      "source": "doaj",
      "url": "https://doi.org/10.3389/fonc.2026.1926332"
    },
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1926332",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1926332/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RC254-282",
      "subfield": "oncology"
    }
  ],
  "title": "TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia",
  "title_text": "TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:43:11Z",
  "url": "https://research.draconitic.com/paper/ey116g649ayhp",
  "venue": "Frontiers in Oncology",
  "versions": []
}